Efficacy and safety of Canagliflozin in subjects with type 2 diabetes mellitus on background metformin
A Januszewicz, F Lavalle González, J Davidson, R Qiu, C Tong, G Hamilton, G Meininger · Diabetologie und Stoffwechsel · 2013 · Heft 04
Bibliografische Angaben
Zusammenfassung
Question: Canagliflozin (CANA) is a sodium glucose co-transporter 2 inhibitor in development for the treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of CANA in subjects with T2DM inadequately controlled with metformin (MET). Methodology: In this randomised, double-blind, Phase 3 study, subjects with T2DM on stable MET (N = 1,284) received CANA 100 or 300 mg, sitagliptin (SITA) 100 mg, or placebo (PBO) daily (2:2:2:1) for a 26-week, PBO- and active-controlled period (results reported here) followed by a 26-week, active-controlled period (PBO subjects switched to SITA; re…
